Granulocyte / macrophage -colony-stimulating factor (GM-CSF), an immunomodulator of hematopoietic cells, has also been shown to stimulate human keratinocyte proliferation in vitro and speed healing of wounds in the skin oflepromatous leprosy patients. In this study we have examined the in vivo effects of recombinant human GM-CSF on epidermal keratinocyte proliferation and on expression of proteins marking regenerative epidermal growth. Skin biopsies from GM-CSF injected cutaneous sites were obtained between 1 and 6 d following administration of7.5 or 15 ILg of the growth factor. Activation of keratinocyte proliferation, quantified as the expression of the Ki67+ nuclear antigen, was noted 1 d following GM-CSF ad-G ranuloctye/macrophage-colony-stimulating factor (GM-CSF) is a 23-kd glycoprotein that regulates the proliferation and differentiation of hematopoietic cells [1] . GM-CSF also plays a significant role as an immunomodulator, activating macrophages, thus promoting the killing of intracellular pathogens [2] . In addition, the cytokine mediates the maturation of epidermal Langerhans cells and bone marrow -derived dendritic cells [3 -5] . Recently we demonstrated that GM-CSF stimulates keratinocyte proliferation ill vitro and speeds healing of skin wounds in lepromatous leprosy patients [6, 7] ' Normal human epidermis displays two alternative states ofkeratinocyte growth and differentiation: 1) a "normal" state oflow-level proliferation and ordered differentiation to maintain tissue homeostasis, and 2) a "regenerative" or "alternative" pathway of increased proliferation and more rapid cellular maturation that is associated with healing of skin wounds and a variety of hyperproliferative epidermal pathologies. The "regenerative" keratinization path~ay outlined by Mansbridge et al [8] highlighted the altered expressIOn of several structural keratinocyte proteins detected by indirect immunofluorescence or immunoperoxidase antibody staining during wound healing and in psoriatic epidermis. Altered expression of involucrin, filaggrin, and keratins 6/16 mark the "alternative" maturation pathway of keratinocytes associated with this regenera- tive epidermal phenotype [8] . Ki67, a nuclear antigen, has been demonstrated to be an active marker of cellular proliferation [9, 10] . The antigen is normally absent in quiescent cells but is expressed in proliferating cells during the S, G2, and M phases of the cell cycle lll]. In the present study we have directly evaluated the effect of GM-CSF injection into the skin oflepromatous patients on keratinocyte maturation and proliferation. Our results suggest GM-CSF directly affects keratinocyte proliferation and regenerative differentiation of the epidermis.
MATERIALS AND METHODS
Patients Twenty patients with lepromatous leprosy were selected for GM-CSF administration as previously described [7] .
Study Design Patients were seen at the Clinical Branch of the Leonard Wood Memorial Center for Leprosy Research, Cebu City, Philippines [7J. Recombinant GM-CSF was supplied by Sandoz AG (Basel, Switzerland). Intradermal injections of either 7.511g or 15.0 I1g of GM-CSF produced in CHO cells (GM 89-107) (batch 4026 0188) were administered daily as described [7] . Patients were randomly assigned to receive a repeated injection of GM-CSF at a previously administered site. A 4-mm punch biopsy was taken on entry to the srudy. Injection site biopsies were performed at specific time intervals after GM-CSF administration. All 20 patients were biopsied at time O. Four patients were biopsied after 24 11, five after 48 h, four after 72 and 96 h, and three after 120-144 h. Ten additional biopsies were performed on patients who underwent reinjection. A final biopsy was taken from an uninvolved site on day 11. All injections were given in skin of the back of patients [7] .
hnmunohistochemistry Biopsy specimens were fixed in neutral buffered 10% formalin overnight, embedded in paraffin, and sectioned. Sections were deparaflinized in xylene and decreasing concentrations of ethanol mixed with phosphate-buffered saline solution (PBS). Two distinct immu-0022-202X/94/S07.00 Copyright © 1994 by The Society for Investigative Dermatology, Inc. 601 noperoxidase techniques were initially performed. The specimens to be stained with the Ki67 nuclear antibody (AMAC, Inc., Westbrook, Maine) underwent trypsinization for 10 min and were fixed in cold, 100% acetone. Activation of cellular proliferation was quantified by the counting ofkeratinocytes expressing Ki67+ nuclei located in the basal or immediately suprabasal epidermis and presented as a percentage of 100 total basal cells. Specimens to be examined for keratinocyte cytoplasmic proteins were fixed with acetone:methanol, 1:1. The antibodies directed against filaggrin and involucrin [8] were obtained from Biomedical Technology, Inc., MA. Monoclonal antibody AE-1 was a generous donation from Dr. T.-T. Sun. The regenerative maturation phenotype was defined as premature expression of filaggrin and involucrin by lower spinous keratinocytes and induced expression of keratin 16 (detected by antibody AE-1). lmmunoperoxidase studies were performed using the Vectastain ABC kit (Vector Laboratories, Burlingame, CAl as described previously [12, 13] ' Negative controls were performed for all immunoperoxidase studies.
Determination of Epidermal Thickness Epidermal thickness was evaluated by direct examination of hematoxylin-stained sections using a computer-based image digitizing system (Southern Micro Instruments, Inc., Atlanta, GA) [7] .
Statistical Analysis Biopsy specimens were divided into pre-and posttreatment groups. Differences in the incidence of Ki67+ cells and the expression of a regenerative maturation phenotype were analyzed using a chi-square model.
RESULTS
Injection of GM-CSF intradermally into the skin of patients with lepromatous leprosy produced epidermal thickening (acanthosis) that peaked by 24 -48 h, persisted for up to 6 d after injection, and had returned fully to basal levels by 11 d (Fig IA) . To establish whether acanthosis was the result of keratinocyte hyperplasia, hypertrophy, or a combination of the two, skin section sites were stained with antibodies detecting the nuclear antigen Ki67 (hyperplasia) and the cellular proteins filaggrin, involucrin, and keratin 16. Intradermal injection of human rGM-CSF increased keratinocyte proliferation as demonstrated by an enhanced number of Ki67+ keratinocytes in the epidermis. The number ofKi67+ keratinocytes was enhanced by 24 h and peaked within 48 h after rGM-CSF injection (Fig IB) . There were still substantial increases in the number of Ki67+ nuclei after 96 h.
Because the peak of epidermal thickening preceded peak keratinocyte proliferation, we examined the role ofkeratinocyte differentiation in GM-CSF-induced epidermal acanthosis. The ability of rGM-CSF injection to induce regenerative maturation was assessed by staining with antibodies directed against filaggrin, a protein normally associated with keratin filaments in keratohyaline granules, and involucrin, a membrane protein crosslinked by transglutaminase as part of normal keratinocyte terminal differentiation. Although these cellular proteins are normally expressed in the granular layer of the epidermis, premature expression of filaggrin and involucrin occurs in lower spinous keratinocytes in regenerating epidermis. Increased premature expression of filaggrin was observed as early as 1 dafter rGM-CSF injection (Fig Ie) . Similarly, the incidence of premature expression of involucrin in lower spinous keratinocytes was also noted as early as 1 d after the administration of rGM-CSF (Fig Ie) . The increased presence of confluent regenerative maturation was detected for both involucrin (p = 0.009) and filaggrin (p = 0.067) following GM-CSF administration. The expression of AE-l reactive keratins in intrafollicular keratinocytes was absent prior to GM-CSF injection; however, several patients demonstrated focal induced expression of the keratin-16 protein following cytokine administration (see below). Figure 2 illustrates the histologic staining patterns of Ki67+ keratinocyte nuclei, involucrin, filaggrin, and keratin 16 in skin following GM-CSF injection. A single injection of rGM-CSF resulted in keratinocyte activation in vivo as evidenced by increased proliferation and increased expression of the regenerative maturation phenotype. This growth-activated phenotype is identical to that observed in acute wounds and hyperproliferative epidermal diseases [14] . 
DISCUSSION
Because GM-CSF is produced not only by immune cells but also by keratinocytes [15] , it is a potential autocrine or paracrine regulator of epidermal growth. Under normal conditions, keratinocyte GM-CSF gene expression and production of GM-CSF are limited. However, under several conditions, including infection and tissue injury, the local production of interleukin 1 and tumor necrosis factor-a lead to increased expression of GM-CSF mRNA and increased production of GM-CSF [16, 17] . It is postulated that an increase in GM-CSF would result in increased wound healing, as well as activation of macrophages and Langerhans cells, thereby enhancing the host's local cellular immune defense. A common occurrence with therapeutic GM-CSF administration (intravenously or subcutaneously) is the occurrence of a disseminated cutaneous eruption characterized by erythematous macules and papules [18] . Erythematous lesions also develop frequently at sites of subcutaneous GM-CSF injection [19] . Histopathologic characterization of the wide-spread lesions has shown a neutrophil-predominant infiltrate in the dermis, which is also accompanied by macrophage influx, epidermal intracellular adhesion molecule-l expression, epidermal edema, occasional keratinocyte dysplasia, and variable lymphocyte influx [18] . These effects clearly differ from those seen in this study in which intradermal GM-CSF administration produced primarily epidermal effects, in association with an influx of dermal Langerhans cells, but not appreciable increases in macrophages or T lymphocytes [7] . Some of the differences observed between studies may be related to larger quantities of GM-CSF used for agranulocytosis, to the route of GM-CSF administration, or to the disease background in which GM-CSF is administered. The results presented in this report demonstrate that a single intradermal injection of GM-CSF can alter keratinocyte proliferation and differentiation. As GM-CSF functions as a mitogen for human keratinocytes in culture [6], GM-CSF could function in human skin in .vivo as an epidermal mitogen, directly regulating proliferation and/or differentiation of keratinocytes. It should be acknowledged, however, that the effects of GM-CSF on epidermis could be mediated indirectly through secondary cytokines induced by GM-CSF. For example, interleukin-6 is rapidly induced in some patients following GM-CSF administration [20] ; interleukin-6 is a mitogen for human keratinocytes in culture and increased production is associated with keratinocyte hyperplasia in psoriasis, suggesting that it is also a candidate mitogen for human keratinocytes in intact epidermis [21] . GM-CSF does not increase transforming growth factor-a production by keratinocytes in an explant model [22] , nor does it increase epidermal growth factor receptor expression, suggesting that GM-CSF does not function as a pan-activator of autocrine growth circuits for epidermal keratinocytes.
Previous studies have shown that physical trauma to the epidermis, e.g., the removal of the stratum corneum by tape-stripping, can induce the regenerative epidermal phenotype, an alternative pathway of keratinocyte differentiation. Interestingly, this alternative pathway of keratinocyte differentiation is persistently present in uninjured epidermis associated with inflammatory skin pathologies such as psoriasis and lichen planus. Although keratinocyte proliferation is increased in many of these disorders and an increased abundance of several cytokines has been noted, no molecular inducers of regenerative epidermal growth have previously been identified. The results of the present study identify GM-CSF as a probable regulator of regenerative epidermal growth, although other cytokines might also induce this epidermal phenotype. The production of GM-CSF by numerous cellular elements associated with infiltrating cells in skin wounds, psoriasis, and other inflammatory dermatoses, suggests that GM-CSF could be the molecular link between cellular immune elements infiltrating skin and induction of an altered epidermal phenotype. GM-CSF may also have a potential therapeutic role in modifying the healing of acute or chronic skin wounds.
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